Device Trial Radar · NCT06507423
Performance of the SeptiCyte LAB Test for Antibiotic Stewardship in Mesenteric Ischemia
Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Aug 1, 2024
Primary completion
Sep 1, 2024
Study completion Nov 1, 2024
Sponsor
- Lead sponsor
- Central Hospital, Nancy, FranceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 18, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will help determine whether the SeptiCyte LAB test can accurately differentiate between SIRS and actual infections in postoperative patients, potentially reducing unnecessary antibiotic use and improving patient outcomes in cases of acute mesenteric ischemia
Conditions
- Acute Mesenteric Ischemia
- Sepsis Bacterial
- Intra-abdominal Infection
- Digestive Inflammation
Interventions
Septicyte Lab Test pre operativeDevice
SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response. Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively.
Septicyte Lab Test post operativeDevice
SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response. Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence or absence of bacterial coinfection during acute mesenteric ischemiaTime frame: Day 0 (pre operative)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHRU de Nancy
Nancy, Lorraine, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.